Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors

British Journal of Cancer

Volumn 91, Issue 12, 2004, Pages 2005-2011

  Hitt, R ^a   Jimeno, A ^a,b   Rodriguez Pinilla M ^a   Rodriguez Peralto J L ^a   Millan J M ^a   Lopez Martin A ^a   Brandariz, A ^a   Pena C ^a   Cortes Funes H ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Capecitabine; Cisplatin; Head and neck squamous cell carcinoma

Indexed keywords

ANGIOGENIC FACTOR; CAPECITABINE; CISPLATIN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; FEMALE; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; MALE; MICROVASCULATURE; MICROVESSEL DENSITY; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INDUCING AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 12344270059     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602275     Document Type: Article

References (26)

1. Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R (2000) Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 60: 6298-6302
2. Buchler P, Reber HA, Buchler MW, Friess H, Hines OJ (2002) VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg 236: 738-749; discussion 749
3. Campbell JB, Dorman EB, McCormick M, Miles J, Morton RP, Rugman F, Stell PM, Stoney PJ, Vaughan ED, Wilson JA (1987) A randomized phase III trial of cisplatinum, methotrexate, cisplatinum + methotrexate, and cisplatinum + 5-fluoro-uracil in end-stage head and neck cancer. Acta Otolaryngol 103: 519-528
4. Clavel M, Vermerken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M (1994) Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5: 521-526
5. Dimery IW, Hong WK (1993) Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85: 95-111
6. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098
7. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10: 1245-1251
8. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H (1998a) Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58: 685-690
9. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H (1998b) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55: 1091-1097
10. Jacobs C (1994) Head and neck cancer in 1994: a change in the standard of care. J Natl Cancer Inst 86: 250-252
11. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L et al. (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257-263
12. Kaplan E, Meier P (1958) Nonparametric estimation for incomplete observations. J Am Soc Stat Assoc 53: 447
13. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H (1983) Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull (Tokyo) 31: 175-178
14. Koukourakis MI, Giatromanolaki A, Fountzilas G, Sivridis E, Gatter KC, Harris AL (2000) Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res 6: 381-389
15. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229
16. Liggett JrW, Forastiere AA (1995) Chemotherapy advances in head and neck oncology. Semin Surg Oncol 11: 265-271
17. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110-115
18. Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y (2002) Vascular endothelial growth factor (VEGF) expression correlates with p53 and ki-67 expressions in tongue squamous cell carcinoma. Anticancer Res 22: 1039-1044
19. Okamoto E, Osaki M, Kase S, Adachi H, Kaibara N, Ito H (2001) Thymidine phosphorylase expression causes both the increase of intratumoral microvessels and decrease of apoptosis in human esophageal carcinomas. Pathol Int 51: 158-164
20. O-Charoenrat P, Rhys-Evans P, Eccles S (2001) Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 92: 556-568
21. Pivot X, Chamorey E, Guardiola E, Magne N, Thyss A, Otto J, Giroux B, Mouri Z, Schneider M, Milano G (2003) Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 14: 1578-1586
22. Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, Aoki D, Okumura H, Yamada Y, Akiyama S, Aikou T (1996) The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A: 1227-1232
23. Thall PF, Simon R, Ellenberg SS (1989) A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 45: 537-547
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
25. Veronesi A, Zagonel V, Tirelli U, Galligioni E, Tumolo S, Barzan L, Lorenzini M, Comoretto R, Grigoletto E (1985) High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. J Clin Oncol 3: 1105-1108
26. Zimmerman M, Seidenberg J (1964) Deoxyribosyl transfer. I. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues. J Biol Chem 239: 2618-2621